Now, the experience of Allergan is coupled with AbbVie, a leader in neuroscience

A RESILIENT PURSUIT
TO TRANSFORM LIVES

We are a passionate team, driven to find effective and transformative solutions to the real-life issues patients with post-stroke spasticity face.

WHAT FUELS US?

The drive and determination of patients like Sophia inspire us to better understand everyday challenges, and strive for better outcomes. Hear from Sophia herself:

INT-BTX-2150179 | May 2021

TRUST YOUR EXPERIENCE,
TRUST OUR COMMITMENT

THE PARTNER OF CHOICE

We share your drive to help those affected by post-stroke spasticity. Together, we strive to preserve personhood, working relentlessly to advance learning and expertise.

INT-BTX-2150179 | May 2021

POST-STROKE SPASTICITY REFERRAL TOOL

Because a timely diagnosis may avoid the perpetual
worsening of untreated spasticity, we work closely with thought
leaders to develop tools to identify spasticity sooner

TRUST YOUR EXPERIENCE,
TRUST OUR COMMITMENT

THE TREATMENT OF CHOICE

There is only one BOTOX®. A treatment that owes much to its dedicated research teams and distinct manufacturing process, as well as patients and their carers.

COMMITMENT TO TOXIN RESEARCH

There is still so much to explore, so we are driving research to help us better understand how BOTOX® can benefit more patients.

Early identification and intervention is key for patient outcomes1

Trust BOTOX ® for your post-stroke
spasticity patients2–5

  • BOTOX® has proven evidence and experience in post-stroke spasticity in both the upper and lower limb in a range of muscles 2–4
  • For these patients, BOTOX® showed reduced muscle tone, reduced pain and greater functional goal achievement compared to baseline 3–5
  • Established safety and tolerability, with experience from 30 years of use in a range of conditions 2,6,7

References:

  1. 1. Wissel J, et al. PM R. 2015;7(1):60–67.
  2. 2. BOTOX ® Summary of Product Characteristics. February 2021.
  3. 3. Brashear A, et al. N Engl J Med. 2002;347(6):395–400.
  4. 4. Kaji R, et al. J Neurol. 2010;257:1330–1337.
  5. 5. Gordon MF, et al. Neurology. 2004;63(10):1971–1973.
  6. 6. Naumann M, et al. Eur J Neurol. 2006;13(Suppl 4):35–40.
  7. 7. Jabbari B. Tremor Other Hyperkinet (N Y) 2016;6:394

BOTOX® (botulinum toxin type A) Prescribing and adverse event reporting information Italy >

European (MRP) Prescribing Information >

Adverse Events should be reported to your local regulatory authority and Allergan Office.

In Italy, BOTOX® is indicated and reimbursed by SSN for the management of focal spasticity of the wrist and hand in adult post-stroke patients and focal spasticity of the ankle in adult post-stroke patients.
BOTOX® may not be registered in your country or license terms may vary by country. Please refer to your local prescribing information before prescribing any product.
Materials developed under central/Irish product licence.
Botulinum toxin units are not interchangeable from one product to another; doses recommended in Allergan Units are different from other botulinum toxin preparations. A list of countries with this product/indication is available from UK_Medinfo@Allergan.com.

For Italy only: Classe: H-USPL. Ad uso esclusivo in centri ospedalieri e strutture assimilabili e da specialisti: Neurologo (neuropsichiatra), Neuropsichiatra infantile, Medico specialista in medicina fisica e riabilitativa, Neurofisiopatologo, Oculista, Ortopedico, Urologo, Dermatologo, specialista in Odontoiatria e Odontoiatra. Vietata la vendita al pubblico. Prezzo ex factory (IVA esclusa): € 142,99.

Developed and funded by Allergan, an AbbVie company.

May 2021
INT-BTX-2150167
Submitted to AIFA on 24/05/2021